select only the abnormal samples for quantitative analysis and at the same time would indicate the proper dilution and serve as a control for these assays.
Furthermore, since many more tests could be performed, a greater percentage of patients with elevated alkaline phosphatase activity would be detected. The use of a commercial reagent tablett designed to meet this need is discussed in this paper.
The purpose of the study reported in this article was twofold. In the first place, the validity of the reagent when used semiquantitatively was to be tested.
Secondly, a 5-mo. study was undertaken to determine what percentage of the alkaline phosphatase assays recuested at Morristown Memorial Hospital yielded normal values. In addition, it was thought desirable to determine how many patients for whom no assay was requested had unsuspected abnormal levels.
BABSON ET AL.
Clinical Chemistry For the purpose of this study, only values of 6.0 Bodansky units or more per 100 ml. were considered as clinically significant.
MATERIALS AND METHODS

The
The semiquantitative assay was performed according to the directions of the manufacturer.
Four drops of serum or plasma were added to a substrate tablet in a small tube. The tablet was dissolved, and the tube was allowed to stand for about 20 mm., the exact time depending on the room temperature.
One drop of 0.5N NaOH was added to terminate the reaction. The color produced by the phenolphthalein liberated from stabilized phenolphthalein phosphate was compared with the color chart. The quantitative assay used was a standard modification (5) of the Bodansky procedure (6), using the buffered substrate at pH 9.4.
RESULTS
VALIDITY OF THE NEW METHOD
The results for the 117 samples assayed by both procedures are separated into seven groups as shown in Table 1 . The reaction colors of the sera of Groups 1, 3, 5, and 7 matched the four color-chart colors intended to correspond to 3, 6, 12, and 22 Bodansky units per 100 ml., More important, however, is the fact that of the 70 sera that gave less than borderline color, not one assayed quantitatively at more than 6.0 Bodansky units per 100 ml.; that is, there were no false negatives.
In the 117 samples, no false positives were found (greater than borderline color by the present method and less than 6.0 Bodansky units per 100 ml. by quantitative assay).
SCREENING STUDY
There was good agreement between the quantitative results for sera assayed at the two laboratories.
The results of the analyses were broken down as follows. (1) A total of 1809 sera gave less than borderline color by the present method and were therefore not assayed quantitatively; (2) 117 gave borderline color, and of these 59 were shown by quantitative assay to contain less than 6.0 Bodansky units per 100 ml., and 52 to contain 6.0 or more units per 100 ml.; and (3) 74 gave more than borderline color. Two sera in the last group were false positives, giving slightly more than borderline color, although by quantitative assay they contained less than 6.0 Bodausky units per 100 ml. Thus, a total of 124 sera were abnormal.
The hospital laboratory had received requests from attending physicians for quantitative alkaline phosphatase assays of 85 of the 2000 sera. By the present method, 61 of these 85 sera gave less than borderline color, while 6 gave borderline color; by the quantitative test all of these samples were shown to contain less than 6.0 Bodansky units per 100 ml. The remaining 18 samples yielded elevated levels by both methods.
The distribution of the elevated samples in terms of Bodansky units per 100 ml. is shown in Fig. 1 . The diagnoses of patients whose sera contained more than 12 Bodansky units per 100 ml. but which were not assayed at the hospital laboratory are recorded in Table 2 . phosphatase activity had the analysis been requested by the attending physicians.
DISCUSSION
It is interesting to note the variety of diagnoses usually associated with elevated levels in which a highly abnormal level of alkaline phospbatase was encountered (Table 2) . A similar 
